Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines

The Lancet Neurology - Tập 3 - Trang 618-621 - 2004
Ettore Beghi1
1Epilepsy Center, University of Milano-Bicocca, Ospedale “San Gerardo”, Monza, and the Laboratory of Neurological Disorders, Institute for Pharmacological Research “Mario Negri”, Milano, Italy

Tài liệu tham khảo

Hauser, 1993, Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984, Epilepsia, 34, 453, 10.1111/j.1528-1157.1993.tb02586.x Hauser, 1991, Prevalence of epilepsy in Rochester, Minnesota: 1940–1980, Epilepsia, 32, 429, 10.1111/j.1528-1157.1991.tb04675.x French, 2004, Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy, Neurology, 62, 1252, 10.1212/01.WNL.0000123693.82339.FC French, 2004, Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy, Neurology, 62, 1261, 10.1212/01.WNL.0000123695.22623.32 French, 1999, Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy, Neurology, 52, 1540, 10.1212/WNL.52.8.1540 Wong, 2000, Adverse reactions to new anticonvulsant drugs, Drug Saf, 23, 35, 10.2165/00002018-200023010-00003 Sheridan, 1996, The development of antiepileptic drugs for children: report from the NIH workshop, Bethesda, MD, Feb 17–18, 1994, Epilepsy Res, 23, 87, 10.1016/0920-1211(95)00043-7 Beghi, 2001, Epilepsia, 42, 1422, 10.1046/j.1528-1157.2001.11201.x Karceski, 2001, The expert consensus guideline series: treatment of epilepsy, Epilepsy Behav, 2, A1, 10.1006/ebeh.2001.0283